Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

This isn't the first time Lilly has expanded the supply of its weight-loss drug and cut its cost to effectively ... GLP-1 agonists are a class of Type 2 diabetes drugs that improve blood sugar ...

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and ...

Lilly is launching two new doses and cutting prices for self-paying customers Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and ...

Just days after Eli Lilly announced plans to cut the price of its insulin products in the US, Novo Nordisk has followed suit with reductions of up to 75% from the start of next year. The discount ...

Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1, ...

While health insurers often cover diabetes drugs such as Ozempic and ... On Feb. 25, Novo Nordisk's competitor, Eli Lilly, cut the monthly price for lower-dosage vials of Zepbound by $50 for ...

Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma A/S (CSE:ZELA).